How can confectionery navigate the Ozempic effect?

The growing popularity of medications like Ozempic, Wegovy, and Mounjaro – initially developed for managing type 2 diabetes – is poised to reshape consumer habits and, unexpectedly, the travel retail confectionery market. As these treatments transition toward broader use as oral weight-loss solutions, businesses catering to travelers are preparing for a shift in how and why people purchase sweets.

The “Ozempic Effect” and Changing Consumer Behavior

The impact of Glucagon-like peptide (GLP-1) drugs is already being felt. In the United States, nearly 20% of individuals aged 50-64 – a key demographic for travel spending – have used these medications. In the UK, usage has surpassed 10%. JP Morgan Research forecasts the global GLP-1 market will exceed $100 billion by 2030, signaling a significant and lasting trend.

Did You Know? Traditionally, the travel retail confectionery sector has relied on volume-based indulgence for a hefty slice of its overall revenue.

These drugs work by altering brain chemistry, often diminishing intense sugar cravings. Users report that sweets can taste overly sweet, and even moderate consumption of high-sugar, high-fat items can cause physical discomfort due to delayed gastric emptying.

Industry Response and Potential Strategies

While publicly downplaying the potential impact, confectionery giants are already adapting. Mondelēz International CEO Dirk Van de Put anticipates a volume dip of only 0.5% to 1.5% over the next decade. However, companies like Nestlé are proactively launching products tailored to the needs of GLP-1 users, such as the Vital Pursuit line of high-protein, fiber-rich frozen foods in the US.

For the travel retail sector, the key is to move away from relying on impulse purchases of large quantities. Instead, operators should focus on premiumization, offering smaller portions of high-quality, functional confectionery.

Expert Insight: The shift towards GLP-1 medications represents a fundamental change in consumer psychology. The traditional appeal of oversized, indulgent treats is diminishing, requiring retailers to rethink their product offerings and store layouts to cater to a more mindful and health-conscious traveler.

This could involve offering premium “bites” in collectible, souvenir-style tins, appealing to travelers seeking a small, controlled luxury or a unique gift. There’s also an opportunity to expand offerings of GLP-1-friendly snacks, such as dark chocolate with prebiotic fiber, ginger-infused sweets, and high-strength mints.

Rethinking the Retail Experience

A redesign of duty-free confectionery stores could also be beneficial. High-volume promotional areas could be supplemented with “Wellness & Satiety” zones, aligning with the growing demand for healthy snacking options like nuts, seeds, and dried fruits.

The rise of GLP-1 drugs doesn’t necessarily signal the end of confectionery, but it does demand innovation and diversification. A focus on high-value, mindful indulgence could ensure the category remains appealing to the modern traveler.

Frequently Asked Questions

What are GLP-1 medications?

GLP-1 medications, such as Ozempic, Wegovy, and Mounjaro, are treatments initially developed for type 2 diabetes that have become popular for weight loss.

How do these medications affect confectionery sales?

These drugs can reduce sugar cravings and cause discomfort when consuming high-sugar, high-fat foods, potentially leading to a decline in impulse purchases of traditional confectionery items.

What strategies can confectionery retailers use to adapt?

Retailers should focus on premiumization, offering smaller portions of high-quality, functional confectionery, and potentially creating dedicated “Wellness & Satiety” zones within their stores.

As consumer preferences continue to evolve with the increasing use of these medications, how might the travel retail industry further adapt to prioritize mindful indulgence and cater to changing health priorities?